Engineered Alpha-Galactosidase Variants for Fabry Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy, face challenges including poor stability of the enzyme at physiological pH, limited cellular uptake, and immunogenicity, which hinder effective globotriaosylceramide clearance and symptom management.
Innovation Solution
Engineered human alpha-galactosidase polypeptides with optimized sequences for improved thermostability, serum stability, reduced immunogenicity, enhanced cellular uptake, and increased globotriaosylceramide clearance are developed, addressing the limitations of existing therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used for Fabry disease, then globotriaosylceramide clearance is achieved, but the enzyme exhibits poor stability at physiological pH and limited cellular uptake
Solution Approach 1:
The patent applies parameter changes by modifying amino acid residues at specific positions (e.g., positions 44, 143, 217, 247, 302, 316, 322, 337, 362, 373) to alter the enzyme's physical and chemical properties. These substitutions (such as R44L, E143Q, R217F, D247N, K302Q, D316L, I322M, P337A, Q362K, K373R) change the enzyme's stability parameters and cellular interaction properties, resolving the contradiction between stability and clearance efficacy
Solution Approach 2:
The patent creates composite enzyme variants by combining multiple amino acid substitutions within a single polypeptide chain. These composite modifications (e.g., R44L/E143Q/R217F/D247N/K302Q/D316L/I322M/P337A/Q362K/K373R) work synergistically to simultaneously improve thermostability, serum stability, and cellular uptake while maintaining enzymatic activity for globotriaosylceramide clearance
2Ease of operation
If current enzyme replacement therapy is administered, then some globotriaosylceramide clearance occurs, but the enzyme shows reduced immunogenicity issues and poor cellular uptake
Solution Approach 1:
The patent modifies immunogenicity parameters by substituting amino acids at positions known to elicit immune responses (such as R217F, K373R, Q362K). These changes reduce the enzyme's immunogenicity while the substitutions at positions like 44, 143, and surface-exposed residues enhance cellular uptake efficiency, resolving the contradiction between ease of operation and harmful factors
3Temperature
If standard alpha-galactosidase is used, then enzymatic activity is maintained, but thermostability and serum stability are poor
Solution Approach 1:
The patent applies parameter changes by introducing amino acid substitutions that specifically enhance thermostability (e.g., R44L, I322M, P337A) and serum stability (e.g., E143Q, D247N, K302Q). These substitutions strengthen the enzyme's structural integrity and resistance to proteolytic degradation while preserving the catalytic active site and substrate binding capability, thus maintaining enzymatic activity consistency across varying temperatures and serum conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered alpha-galactosidase polypeptides demonstrate enhanced stability, improved cellular uptake, and increased efficacy in clearing globotriaosylceramide, potentially leading to better symptom management and reduced side effects compared to current treatments.
Implementation Method 1
Human alpha galactosidase ('GLA'; EC 3.2.1.22) is a lysosomal glycoprotein responsible for hydrolyzing terminal alpha galactosyl moieties from glycolipids and glycoproteins
Data Source
AI summary
Engineered human alpha-galactosidase polypeptides and compositions thereof are provided. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes are described.